WO2002006305A1 - Procede permettant de recueillir l'enveloppe virale d'un baculovirus - Google Patents

Procede permettant de recueillir l'enveloppe virale d'un baculovirus Download PDF

Info

Publication number
WO2002006305A1
WO2002006305A1 PCT/JP2001/006109 JP0106109W WO0206305A1 WO 2002006305 A1 WO2002006305 A1 WO 2002006305A1 JP 0106109 W JP0106109 W JP 0106109W WO 0206305 A1 WO0206305 A1 WO 0206305A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
protein
target protein
membrane
envelope
Prior art date
Application number
PCT/JP2001/006109
Other languages
English (en)
Japanese (ja)
Inventor
Takao Hamakubo
Tatsuhiko Kodama
Hiroko Iwanari
Yukio Itoh
Original Assignee
Institute Of Immunology Co., Ltd.
Center For Advanced Science And Technology Incubation, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Immunology Co., Ltd., Center For Advanced Science And Technology Incubation, Ltd. filed Critical Institute Of Immunology Co., Ltd.
Priority to AU2001271050A priority Critical patent/AU2001271050A1/en
Publication of WO2002006305A1 publication Critical patent/WO2002006305A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to a method for recovering a virus envelope from a baculovirus germination virus. More specifically, the present invention relates to a method for recovering a virus envelope from a germinated virus, which comprises treating the budding virus of the Baculovirus expressing the protein of interest with a physicochemical technique. The present invention also relates to a method for screening a chemical substance, a method for producing an antibody, and a method for purifying a target protein using the above-mentioned recovery method.
  • Background art
  • a protein expression system using baculovirus and insect cells is widely used as a membrane protein expression system. Compared to expression systems using Escherichia coli or yeast, such an expression system has the advantage that it does not easily form aggregates and contains post-translational modifications necessary for protein functions such as sugar chain addition and metal ion coordination. There are many.
  • the baculovirus expression system is a system for expressing a target gene in large amounts in insect cells by using a promoter of a viral gene such as a baculovirus polyhedrin protein.
  • the expressed protein is recovered from insect cells, but the seven transmembrane receptors (Loisel TP, Ansanay H, St-Onge S, Gay B, Boulanger P, Strosberg AD, Marullo S, Bouvier M., Nat Biotechnol 1997 Nov; 15 (12): 1300-4., Recovery of homogeneous and functional beta 2-adrenergic receptors from extracellular baculovirus particles.) ⁇ Japanese Patent Application No. 2000-0- 15 8 2 9 4 Various membrane proteins have been reported to be expressed in the viral envelope.
  • Membrane proteins expressed in the viral envelope are proteins expressed in insect cells It has been reported that the proportion of proteins that retain their functions is higher than that of proteins. In other words, in addition to using proteins expressed in insect cells such as Sf9, a new method using membrane proteins expressed in the envelope of the virus has been considered. It has come to be. In addition, a monoclonal antibody against the target protein was prepared using the method of fusing the target protein to gp64, the only viral membrane protein present in the viral envelope, and displaying it on the viral envelope (Novagen, pBACsurf-1 expression system). Reported how to
  • a protein expressed in a budding virus in addition to a system using a protein expressed in insect cells such as Sf9 and a system using a secreted protein as in the past.
  • the system to be used is beginning to be used for the production of monoclonal antibodies.
  • Baculoviruses have two life cycles: occlusion derived virus (OCD) and budded virus (BV), which are adapted to the process of infection between insects and between cells in individuals. are doing. Both consist of a viral DNA and a viral membrane called the virion envelope, which surrounds a part called nucleocapsid, which is made of structural proteins. Only gp64 is known as a virus-derived membrane protein in the virus envelope. The membrane protein expressed in the budding virus is considered to be present in the virus envelope.
  • OCD occlusion derived virus
  • BV budded virus
  • Membrane proteins include receptors for hormones and chemicals, channel proteins, proteins involved in mass transport, adhesion factors, membrane enzymes, enzyme substrate proteins, enzyme activators, proteins involved in antigen presentation, higher order It has important functions related to the physiological functions of cells, such as proteins involved in structure formation. Express these membrane proteins and use their functions Building a system that can be used is an important technology that will lead to the development of pharmaceuticals, biosensors, and monoclonal antibodies.
  • an object of the present invention is to provide a method for separating a nucleocabside of a budding virus from a virus envelope and recovering a virus membrane fraction (enucleated virion envelope, EVE) in which a target membrane protein is expressed. did.
  • the present invention solves the problem of providing a method for screening a chemical substance, a method for producing an antibody, and a method for purifying a target protein using the above-mentioned method for recovering a viral membrane fraction in which a target membrane protein is expressed. It should be a task to be done.
  • the present inventors have conducted intensive studies in order to solve the above-mentioned problems.
  • the baculovirus budding virus (Budded Virus) was subjected to a physicochemical method (specifically, a combination of surfactant treatment and density gradient centrifugation).
  • the present invention succeeded in separating the nucleoside peptide of the budding virus from the virus envelope, and recovering the virus membrane fraction (enucleated virion envelope, EVE) in which the target membrane protein was expressed. It was completed.
  • a method for recovering a virus envelope by separating a nucleoforce of the budding virus and a virus envelope, comprising treating the baculovirus germinating virus expressing the target protein by a physicochemical technique.
  • a virus envelope in which a target protein obtained by the method according to any one of (1) to (4) has been expressed a polyclonal antibody against the target protein expressed on the virus envelope or A method for producing a monoclonal antibody.
  • FIG. 1 shows the measurement results of sucrose concentration and protein concentration of each fraction obtained by sucrose density gradient ultracentrifugation.
  • FIG. 2 shows the results of silver staining of the 3rd to 18th fractions obtained by sucrose density gradient ultracentrifugation, after 12% polyacrylamide SDS electrophoresis (SDS-PAGE).
  • FIG. 3 is an electron micrograph of the ninth fraction obtained by sucrose density gradient ultracentrifugation.
  • FIG. 4 is an electron microscope image of the tenth fraction obtained by sucrose density gradient ultracentrifugation.
  • FIG. 5 is an electron microscope image of the eleventh fraction obtained by sucrose density gradient ultracentrifugation.
  • Figure 6 shows an electron microscope image of the 12th fraction obtained by sucrose gradient ultracentrifugation. It is. '
  • FIG. 7 shows the results of Western blotting using each fraction obtained by sucrose density gradient ultracentrifugation and a specific antibody against SREBP2.
  • the method of the present invention relates to a method for separating a nucleoside of a budding virus and a virus envelope, which comprises treating a baculovirus budding virus expressing a target protein by a physical-chemical method.
  • the target protein referred to in the present specification is preferably a membrane protein, and more preferably a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme activator, a membrane-bound transport protein, a channel protein, It is a protein selected from membrane structural proteins, proteins involved in adhesion, proteins involved in antigen presentation, and proteins involved in the formation of higher-order structures of proteins.
  • the membrane protein will be described in more detail.
  • membrane-bound broadly means that the protein is present in the plasma membrane of cell membranes and intracellular organelles (eg, endoplasmic reticulum, Golgi apparatus, etc.). Not limited.
  • a membrane-bound receptor, a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme activator or a membrane-bound transport protein S, a channel protein, a structural protein of a membrane, an adhesion-related protein A protein, a protein involved in antigen presentation, or a protein involved in formation of a higher-order structure of a protein is a membrane-bound protein of an intracellular organelle, for example, a protein bound to the membrane of the endoplasmic reticulum or the Golgi apparatus.
  • Membrane-bound receptors include seven transmembrane receptors for hormones, odors, taste, light, etc., one transmembrane receptors for LDL receptor ⁇ scavenger-one receptor, growth hormone dinsulin, TNF, glutamate, etc. Receptors, ion channel receptors such as GABA, acetylcholine, and ryanodine, and those forming complexes with T cell receptors, Fc receptors, and the like.
  • membrane-bound enzymes include HMG-CoA reductase involved in cholesterol metabolism and ACAT -: such as (acyl coenzyme A cholesterol acyltransferase) s 7 a- hydroxylase , and the like.
  • Examples include cytochrome P450 related to detoxification, electron transfer enzymes such as ATP synthase ⁇ cytochrome oxidase and reductase, and NADH-Q reductase present in mitochondria.
  • SIP site 1 protease
  • furin furin
  • PC proprotein convertase
  • S2P site 2 protease
  • Angiotensin converting enzyme Angiotensin converting enzyme
  • ADAMS disintegrin and metal loprotease
  • Examples include membrane lipid metabolizing enzymes such as synthase, phosphatidic acid phosphatase, and phosphatidylserine synthase, and enzymes involved in signal transmission such as adenylate cyclase.
  • membrane-bound enzyme substrate proteins include sterol regulatory protein (SREBP), Notch, Irel, and ATF6 as proteins involved in signal transduction and transcriptional regulation, as well as other amyloid precursor proteins, Tu (tumor necrosis factor) precursors Stem cell factors M-CSF (monocyte colony stimulating factor) precursor ⁇ Klotho.
  • SREBP sterol regulatory protein
  • Notch Notch
  • Irel Irel
  • ATF6 proteins involved in signal transduction and transcriptional regulation
  • Tu tumor necrosis factor
  • M-CSF monoocyte colony stimulating factor
  • the membrane-bound enzyme activators Purese diphosphate (presenil lin), SCAP (SREBP cleavage activating protein), and the like 0
  • Membrane-bound transport proteins include NPC (Niemann-Pick type c) 1, which transports lipids such as cholesterol, ABC (ATP-binding cassette), transposon, caveolin, and fatty acid transport protein. And sugar transports including glucose transport such as GLUT-4 and amino acid transposers such as glutamate tanspoter and serotonin transporter.
  • Secl2 and the like can be mentioned as a membrane protein involved in substance transport between intracellular vesicles.
  • channel proteins that selectively pass molecules that do not pass through the membrane under certain conditions.
  • aquaporin famili which is a selective channel of water
  • potassium, calcium, and sodium ions For example, an ion channel, which is a selective channel for such a channel, may be used.
  • NCAM Neuronal cell adhesion molecu ⁇ e
  • ICAM matrivasive protein
  • Dherin family Dherin family
  • integrin desmocholine
  • desmoglein L-selectin
  • connexin glycoprotein, etc. Is raised.
  • Major histocompatibility complex (MHC) involved in antigen presentation in immune cells calnexin
  • PDI protein disulfide isomerase
  • CFTR cystic nbrosis transmembrane conductance regulator
  • At least one type of recombinant baculovirus containing a gene encoding a target protein as described above is used.
  • Baculovirus a virus that infects insects and causes disease, is an enveloped virus that has a circular double-stranded DNA as a gene and is susceptible to insects such as Lepidoptera, Hymenoptera, and Diptera.
  • the nuclear polyhedrosis virus NPV
  • Polyhedra are composed of a polyhedrin protein with a molecular weight of 31 kDa and are produced in large quantities at the late stage of infection, in which numerous virus particles are embedded.
  • Polyhedra are essential for the virus to survive in nature, but are not necessary for the growth of the virus itself, so even if a foreign gene that you want to express in place of the polyhedron gene is inserted, the virus will not infect at all. And proliferate.
  • baculovirus used in the present invention examples include Autographa californica NPV (AcNP V) of NPV subfamily and Bombyxmori NPV (BmNP V) of silkworm. Of viruses can be used as vectors.
  • AcNPV hosts include Spodoptera frugiperda cells (Sf cells), etc.
  • BmNPV hosts include BmN4 cells, etc. .
  • AcNPV vectors are preferred because Sf cells have a higher growth rate than BmN4 cells and the like, and AcNPV also has the ability to infect human hepatocytes and human fetal kidney cells.
  • Spodoptera Frugiperda cell lines Sf9 and Sf21 have been established from ovarian tissues of S. frugiperda larvae, and are available from Invitrogen, Pharmingen (San Diego, CA), ATCC, and the like. In addition, live insect larvae can also be used as host cell systems.
  • the method of constructing the recombinant virus used in the present invention may be performed according to a conventional method, and for example, can be performed by the following procedure.
  • the gene of the protein to be expressed is inserted into a transfer vector to construct a recombinant transfer vector.
  • the overall size of the transfer protein is generally about several kb to 10 kb, of which about 3 kb is a plasmid-derived skeleton, which is resistant to antibiotic resistance genes such as ampicillin and bacteria. Contains the signal for initiation of DNA replication.
  • a normal transfer vector contains 5 'and 3' regions of the polyhedron gene, each of which is several kb, and when transfection is performed as described below, the target Homologous recombination occurs between the gene and the polyhedron gene. It is preferable that the transfer vector contains a plasmid for expressing the protein gene. Examples of the promotion include the promotion of the polyhedron gene, the promotion of the P10 gene, and the promotion of the capsid gene.
  • the type of transfer vector is not particularly limited.
  • a specific example of the transfer vector is pEVmX as an AcNPV-based transfer vector. IV2, pAc SGl, VL 1392/1393, pAcMP2 / 3, p Ac JPI s pAcUW21, pAcDZl, pB lueBac III, pAcUW 51, pAcAB3, p Ac 360 s pB lueBacHi s s p VT -B ac 33, pAcUWls pAcUW42 / 43 etc.
  • BmNPV transfer vectors examples include ⁇ 283, ⁇ 5, ⁇ 30, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 52, pBKblue, ⁇ Kb 1 ue2, pBF series (Funakoshi Corporation, (Available from Fujisawa Pharmaceutical Co., Ltd.).
  • the above-mentioned recombinant transfer vector is mixed with the virus and then transferred to a cultured cell used as a host, or the above-described vector is added to a cultured cell used as a host previously infected with the virus. Then, homologous recombination occurs between the recombinant transfer vector and the viral genomic DNA to construct a recombinant virus.
  • the cultured cells used as a host include the above-mentioned hosts, and are usually insect cultured cells (such as Sf9 cells and BmN cells). Culture conditions are appropriately determined by those skilled in the art. Specifically, when Sf9 cells are used, culture is preferably performed at about 28 ° C. in a medium containing 10% fetal bovine serum.
  • the recombinant virus thus constructed can be purified by a conventional method, for example, plaque assay.
  • the recombinant virus thus produced cannot transform into a polyhedron because foreign DNA has been substituted or inserted into the gene region of the polyhedrin protein of the nuclear polyhedrosis virus. It can be easily distinguished from a replacement virus.
  • the above-mentioned recombinant baculovirus is infected to an appropriate host (cultured cells such as Spodoptera Frugiperda cell lines Sf9 and Sf21, or insect larvae), and after a certain period of time (for example, after 72 hours)
  • the target protein can be recovered by collecting extracellular budding virus (BV) from the culture supernatant by a separation operation such as centrifugation.
  • BV extracellular budding virus
  • the extracellular budding baculovirus can be collected, for example, as follows.
  • the culture of the infected cells is centrifuged at 500 to 1,000 g, and the supernatant containing the extracellular budding baculovirus is recovered.
  • the supernatant is centrifuged at about 30,000 to 500,000 g to obtain a precipitate containing extracellular budding baculovirus.
  • the virus (BV) fraction containing the extracellular budding baculovirus can be obtained by suspending the precipitate in an appropriate buffer.
  • a baculovirus budding virus having a target protein obtained as described above is treated by a physicochemical technique to separate a nucleoforce peptide from a virus envelope.
  • the physicochemical method used in the present invention is not particularly limited as long as it can separate the nucleocabside and the virus envelope from the budding virus of baculovirus, and examples thereof include a treatment with a surfactant and a separation operation by density gradient centrifugation. Alternatively, treatment by freeze-thawing and separation by density gradient centrifugation may be mentioned.
  • the type of surfactant that can be used in the present invention is not particularly limited, and examples thereof include tween 20, triton X 305, and the like, and particularly preferably tween 20.
  • a detergent for treatment with a detergent, mix the fraction containing the budding virus with a detergent solution (for example, a 0.5% tween20 / PBS solution) in a suitable buffer such as PBS, and allow to stand at room temperature for an appropriate time. Can be performed.
  • a detergent solution for example, a 0.5% tween20 / PBS solution
  • a suitable buffer such as PBS
  • freeze-thaw treatment involves suspending the virus (BV) in PBS and cooling to 120 ° C. After 30 minutes, the procedure of returning to room temperature and melting may be repeated, for example, about three times.
  • a method of combining with a hypotonic treatment such as phosphate buffer or water instead of or together with PBS, a method of lowering the temperature further (at 180 ° C or in liquid nitrogen, etc.), and a higher melting temperature.
  • a more rapid freeze-thaw method such as a method at 37 ° C.
  • optimal conditions can be set by appropriately combining such conditions.
  • Examples of other physicochemical methods used in the present invention include ultrasonic treatment and a method in which pressure is applied and pressure is rapidly reduced.
  • sonication there is a method of suspending the virus in PBS and treating it on ice three times for 20 seconds on a machine such as a Branson Sonifier 250, but it is better to perform the treatment under milder conditions. It may be preferable.
  • the method of rapidly vacuum keep over pressure, specifically, N 2 by using an apparatus such as Nitrogen cavitation apparatus, under reduced pressure once and allowed to dissolve N 2 over pressure This method is based on the principle that cells are destroyed by evaporating them.
  • a cell destruction method called French press is also available. Specifically, it is a method in which a cell suspension is broken by applying pressure and passing through a small hole.
  • the means of the physicochemical technique used in the present invention is not particularly limited, but particularly preferably includes a treatment with a surfactant and a separation operation by density gradient centrifugation.
  • the baculovirus budding virus is treated with a surfactant or freeze-thawing as described above, and then the separation operation is performed by density gradient centrifugation.
  • sucrose density gradient ultracentrifugation for example, sucrose density gradient ultracentrifugation can be performed. Specifically, a sucrose solution is overlaid with a suitable concentration gradient (for example, 66.5%, 45%, and 30%), and a germinated virus-containing solution treated with a surfactant or freeze-thaw on the upper layer. After centrifugation at 100,000 g to 500,000 g (for example, 350,000 g) for a certain time, fractionate from the bottom layer.
  • a suitable concentration gradient for example, 66.5%, 45%, and 30%
  • a germinated virus-containing solution treated with a surfactant or freeze-thaw
  • sucrose concentration refractometer
  • protein concentration Bio-Rad protein assay system, BSA standard
  • SDS-PAGE polyacrylamide SDS electrophoresis
  • the virus envelope obtained by the above method and expressing the target protein is also within the scope of the present invention.
  • the present invention further includes measuring the interaction between the target protein expressed on the viral envelope and the test substance using the virus envelope in which the target protein obtained by the above method is expressed. It relates to screening methods for chemical substances.
  • Chemicals to be screened include, for example, peptides, polypeptides, synthetic compounds, fermented microorganisms, extracts from organisms (including plant or animal tissues, microorganisms, cells, etc.), and their libraries. Is mentioned. Libraries include synthetic compound libraries (such as combinatorial libraries) and peptide libraries (such as combinatorial libraries).
  • the chemicals to be screened may be natural or synthetic, and even if a single candidate chemical is tested independently, a mixture of several candidate chemicals (including ) May be tested. Further, it is also possible to screen a fractionated mixture such as a cell extract, and to repeat the fractionation to isolate a substance having a desired activity.
  • These chemicals include a target protein (preferably a membrane protein, particularly preferably a membrane-bound receptor, a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme, expressed on the virus envelope). Interacting with activators, membrane-bound transport proteins, channel proteins, membrane structural proteins, proteins involved in adhesion, proteins involved in antigen presentation, or proteins involved in the formation of higher-order structures of proteins) And more preferably an inhibitor or an activating drug for the above protein.
  • a target protein preferably a membrane protein, particularly preferably a membrane-bound receptor, a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme, expressed on the virus envelope.
  • a target protein preferably a membrane protein, particularly preferably a membrane-bound receptor, a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme, expressed on the virus envelope.
  • a target protein preferably a membrane protein, particularly preferably a membrane-bound receptor, a membrane-bound enzyme,
  • the present invention further provides a method for producing a polyclonal antibody or a monoclonal antibody against the target protein expressed on the virus envelope using the viral envelope in which the target protein obtained by the above method is expressed, and It relates to a polyclonal antibody or a monoclonal antibody obtained by the method.
  • a virus envelope in which a target protein obtained by the above method is expressed is used as an immunogen.
  • Antibodies can be prepared by a conventional method.
  • a mammal is immunized with the viral envelope in which the target protein is expressed as an antigen
  • blood is collected from the mammal, and the antibody is separated and purified from the collected blood.
  • mammals such as mice, hamsters, guinea pigs, chickens, rats, rabbits, dogs, goats, sheep, and mice can be immunized. Immunization can be performed according to the usual immunization method, for example, by administering the antigen one or more times.
  • antigen administration for example, it is preferable to administer the antigen twice or three times at intervals of 7 to 30 days, particularly 12 to 16 days, and the dose can be appropriately selected.
  • the route of administration of the antigen is also not particularly limited, and subcutaneous administration, intradermal administration, intraperitoneal administration, intravenous administration, intramuscular administration, etc. can be appropriately selected, but injection is performed intravenously, intraperitoneally or subcutaneously. It is preferable to administer by the following method.
  • the antigen may be an appropriate buffer, for example, complete Freund's adjuvant, RAS CMPL (Monophosphoryl Lipid A) + TDM (Synthetic Trehalose Dicorynomy co 1 ate) + CWS (Ce 11 Wall Skeleton) adjuvant system), aluminum hydroxide Can be used after dissolving it in an appropriate buffer containing a commonly used adjuvant, but the above adjuvant may not be used depending on the administration route and conditions.
  • complete Freund's adjuvant RAS CMPL (Monophosphoryl Lipid A) + TDM (Synthetic Trehalose Dicorynomy co 1 ate) + CWS (Ce 11 Wall Skeleton) adjuvant system
  • aluminum hydroxide can be used after dissolving it in an appropriate buffer containing a commonly used adjuvant, but the above adjuvant may not be used depending on the administration route and conditions.
  • the immunized mammal is bred for 0.5 to 4 months, for example, a small amount of serum from the mammal is sampled from an ear vein or the like, and the antibody titer is measured. If the antibody titer rises, administer the antigen an appropriate number of times according to the situation. For example, booster immunization is performed using an antigen of 100 / g to 100000. 1 to 2 months after last dose
  • Blood is collected from the sensitized mammal by a conventional method, and the blood is collected, for example, by centrifugation, precipitation using ammonium sulfate or polyethylene glycol, gel filtration chromatography, ion exchange chromatography, and affinity chromatography.
  • a desired polyclonal antibody can be obtained as a polyclonal antiserum by separating and purifying by ordinary methods such as chromatography such as two-take mouth chromatography.
  • a desired monoclonal antibody can be obtained, for example, by producing a hybridoma by cell fusion between an antibody-producing cell and a myeloma cell line.
  • a hybridoma producing a monoclonal antibody can be obtained by the following cell fusion method.
  • spleen cells As antibody-producing cells, spleen cells, lymph node cells, B lymphocytes and the like from immunized animals are used.
  • the antigen a virus envelope expressing the target protein is used. Mice, rats, and the like are used as animals to be immunized, and administration of the antigen to these animals is performed according to a conventional method. For example, a suspension or emulsion of an adjuvant, such as complete Freund's adjuvant or incomplete Freund's adjuvant, and a germinated baculovirus as an antigen is prepared and administered several times subcutaneously, intradermally, intraperitoneally, etc., to an animal. Immunize the animal.
  • an adjuvant such as complete Freund's adjuvant or incomplete Freund's adjuvant
  • a germinated baculovirus as an antigen
  • spleen cells as antibody-producing cells from the immunized animal and fusing them with myeloma cells by a method known per se (G. Kohler et al. 3 Nature, 256 495 (1975)). High pre-doma can be produced.
  • myeloma cell lines used for cell fusion include P3X63Ag8, P3U1 strain, and Sp2 / 0 strain in mice.
  • a fusion promoter such as polyethylene glycol or Sendai virus is used.
  • HAT hypoxanthine 'aminopterin' thymidine
  • Hybridomas obtained by cell fusion are cloned by limiting dilution, etc., and screened to specifically recognize the desired protein. Thus, a cell line producing a monoclonal antibody can be obtained.
  • the hybridoma is cultured by a usual cell culture method or ascites formation method, and the monoclonal antibody is isolated from the culture supernatant or ascites. It may be purified. Purification of the monoclonal antibody from the culture supernatant or ascites can be performed by a conventional method. For example, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, and the like can be used in appropriate combination.
  • the present invention further provides a method of solubilizing and purifying the target protein, which comprises treating the viral envelope expressing the target protein obtained by the above-described method with a solubilizing agent.
  • a solubilizing agent such as lyso-phosphatidylcholin
  • the virus envelope in which the target protein is expressed is suspended in an appropriate buffer, treated with a lysing agent such as lyso-phosphatidylcholin, and further centrifuged (for example, at 300 rpm). This allows separation into a supernatant and a precipitate.
  • the solubilized autologous protein is recovered in the supernatant.
  • Example 1 Extracellular baculovirus expressing sterol-regulated protein (SREBP-2) treated with surfactant and separation of envelope by ultracentrifugation
  • SREBP-2 Sterol regulatory protein
  • SREBP2 is a transcription factor that regulates cholesterol-dependent transcriptional regulation of intracellular cholesterol regulation enzymes and transport proteins such as LDL receptor and HMG-CoA reductase (Brown MS, Goldstein J., Proc Natl Acad Sci USA 1999 Sep 28; 96 (20): 11041-8, A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood.).
  • SREBP 2 is 1 2 at steady state It is present in the endoplasmic reticulum membrane as a 5 kd twice transmembrane precursor protein.
  • Sf9 cells (Invitrogen) is a 1 Ocm dish at 27 ° C with Grace's supplemented media (GIBCO BRL) containing 10% fetal serum (Sigma), penicillin 100 units / ml, streptmycin 100 jug / ml. Was subcultured.
  • the recombinant baculovirus was prepared according to the instruction manual (Bac-N-BlueTM Transfection Kit, Invitrogen), and Sf9 cells were co-infected with Bac-N-Blue DNA (from ApMNPV) and 4 ⁇ g of pBlueBac-SREBP2 to form SREBP2.
  • a recombinant virus was created.
  • BV fraction (LoiselTP, et al., Nat Biotechnol. 1997 (4) EVE fractionation by virus detergent treatment and sucrose density gradient ultracentrifugation SREBP2 expression BV fraction 250 ⁇ 1 and 0.5% tween20 in PBS solution 250 1 and 1:
  • sucrose concentration refractometer
  • protein concentration Bio-Rad Protein Atsie System, BSA standard
  • Electron microscope observation was performed as follows. A collodion film was applied to a 400 grid mesh for sample observation, and carbon deposition (carbon coating) was performed. In order to easily adsorb the sample, the 400 grid mesh was pre-etched by Ionco overnight. The sample ⁇ was placed on a 400 g mesh and dried, and then negatively stained with a phosphoric acid solution of ginstenic acid ( ⁇ ) and observed.
  • BV was recovered at a sucrose concentration of 44.5 to 34.5% (8 to 13 fractions) in accordance with the evening protein staining, and the nucleoforce pseudo (Fig. 3), the virus envelope (EVE) was concentrated in 12 fractions with a sucrose concentration of 37.0% (Fig. 6), and in the 10 and 11 fractions, a mixture of nucleocabushid and envelope was observed. ( Figures 4 and 5).
  • VP 39 on SDS-PAGE Molecular weight 3 9 kDa protein distributed in agreement with the nucleosid image of the electron microscope, and molecular weight 6 known as the only viral protein present in the virus envelope 6
  • the density of the protein band in SDS-PAGE of gp64 of 4 kilodaltons and the distribution of the envelope image of the electron microscope are in agreement (Fig. 2 and Figs. 3 to 6).
  • these samples were subjected to gel electrophoresis by 8% SDS-PAGE, and then subjected to nitrocellulose membrane (Hybond ECL, Amersham) at 38 V for 20 hours.
  • a salting-out purified antibody (10 zg / ml) of the monoclonal antibody 1C6 (ATCC No CRL-2224) recognizing the carboxyl terminus of SREBP 2 was added at room temperature. Incubate for 1 hour, wash 4 times with TBS (2 OmM Tris-buffered saline, pH 7.4), react with peroxidase conjugated anti-mouse IgG antibody (CAPPEL) for 1 hour, wash with TBS in the same manner, and use ECL reagent (Amersham Pharmacia ), And exposed to an x-ray film.
  • TBS OmM Tris-buffered saline, pH 7.4
  • CAPPEL peroxidase conjugated anti-mouse IgG antibody
  • a simple method for separating a nucleoside peptide of a budding virus and a virus envelope and recovering a virus membrane fraction (enucleated virion envelope, EVE) in which a target membrane protein is expressed is provided.
  • the target membrane protein can be concentrated, and the interference of the Atsushi system with the DNA / nucleoside protein of the virus can be avoided.
  • membrane proteins that have an active site inside the membrane (nucleoside side), proteins that interact with other proteins or chemicals, etc., have a part of the membrane destroyed, and substrates or chemicals added from outside cannot be used. Can reach active sites and interaction sites Need to be. In such cases, EVE technology is better than using the virus itself.

Abstract

L'invention concerne un procédé permettant de recueillir l'enveloppe du virion énucléée (EVE) dans laquelle la protéine cible est exprimée suite à la séparation de l'enveloppe virale de la nucléocapside d'un virus de germination. Plus spécialement, l'invention concerne un procédé permettant de recueillir l'enveloppe virale consistant à traiter un baculovirus de germination dans lequel une protéine cible est exprimée, par un traitement physicochimique, et ainsi à séparer l'enveloppe virale de la nucléocapside d'un virus de germination.
PCT/JP2001/006109 2000-07-17 2001-07-16 Procede permettant de recueillir l'enveloppe virale d'un baculovirus WO2002006305A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001271050A AU2001271050A1 (en) 2000-07-17 2001-07-16 Method of collecting viral envelope from germinating baculovirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-215416 2000-07-17
JP2000215416A JP2002030098A (ja) 2000-07-17 2000-07-17 バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法

Publications (1)

Publication Number Publication Date
WO2002006305A1 true WO2002006305A1 (fr) 2002-01-24

Family

ID=18710842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/006109 WO2002006305A1 (fr) 2000-07-17 2001-07-16 Procede permettant de recueillir l'enveloppe virale d'un baculovirus

Country Status (3)

Country Link
JP (1) JP2002030098A (fr)
AU (1) AU2001271050A1 (fr)
WO (1) WO2002006305A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
EP2301573A1 (fr) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Compositions anticancéreuses et contre les maladies infectieuses, et procédés d'utilisation correspondants
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265785A2 (fr) * 1986-10-16 1988-05-04 Microgenesys, Inc. Polypeptides dérivés du gène d'enveloppe du virus d'immuno-dépression acquise, dans des cellules d'insectes infectées par un baculovirus recombinant
WO1994016681A1 (fr) * 1993-01-29 1994-08-04 Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C Composition de vaccin sous unitaire recombinant vivant et procede de preparation
WO1996004385A2 (fr) * 1994-07-29 1996-02-15 Innogenetics N.V. Proteines purifiees d'enveloppe de virus de l'hepatite c a usage diagnostic et therapeutique
WO1998021338A1 (fr) * 1996-11-08 1998-05-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthese et purification de particules de type virus de l'hepatite c

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761994B1 (fr) * 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265785A2 (fr) * 1986-10-16 1988-05-04 Microgenesys, Inc. Polypeptides dérivés du gène d'enveloppe du virus d'immuno-dépression acquise, dans des cellules d'insectes infectées par un baculovirus recombinant
WO1994016681A1 (fr) * 1993-01-29 1994-08-04 Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C Composition de vaccin sous unitaire recombinant vivant et procede de preparation
WO1996004385A2 (fr) * 1994-07-29 1996-02-15 Innogenetics N.V. Proteines purifiees d'enveloppe de virus de l'hepatite c a usage diagnostic et therapeutique
WO1998021338A1 (fr) * 1996-11-08 1998-05-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthese et purification de particules de type virus de l'hepatite c

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301573A1 (fr) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Compositions anticancéreuses et contre les maladies infectieuses, et procédés d'utilisation correspondants
US8119603B2 (en) 2004-02-02 2012-02-21 Ambrx, Inc. Modified human interferon polypeptides and their uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2399893A2 (fr) 2004-12-22 2011-12-28 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
EP3225248A1 (fr) 2008-07-23 2017-10-04 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
EP4302783A2 (fr) 2010-08-17 2024-01-10 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Also Published As

Publication number Publication date
JP2002030098A (ja) 2002-01-29
AU2001271050A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
WO2002006305A1 (fr) Procede permettant de recueillir l'enveloppe virale d'un baculovirus
CA2436281A1 (fr) Molecules chimeres contenant un module pouvant cibler des cellules specifiques et un module regulant la fonction apoptogene du complexe de permeabilite mitochondriale (ptpc)
EP0345242A2 (fr) Expression de protéines gag de rétrovirus dans les cellules eucaryotes
JP2009183303A (ja) Ｉｃａｍ−１に対するヒト化抗体、それらの生成および使用
WO1999059636A1 (fr) Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
CN104316696A (zh) 用于检测jc多瘤病毒的方法
Rindisbacher et al. Production of Human Secretory Component with Dimeric IgA Binding Capacity Using Viral Expression Systems∗
JP3542784B2 (ja) 抗ｓｅｍｐ１抗体、その製法及び使用
US20080286275A1 (en) Antigen Binding Proteins Directed Against Scavenger Receptor B1 that Inhibit Hcv Replication
US20180016576A1 (en) Novel Therapeutic Agent for Septicemia, and a Method for Screening for Same
Song et al. Characterization of N-glycan structures and biofunction of anti-colorectal cancer monoclonal antibody CO17-1A produced in baculovirus-insect cell expression system
Azali et al. Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review
JP4722048B2 (ja) Ｎ−デアセチラーゼ／ｎ−スルホトランスフェラーゼ２を発現するベクター
JP4596608B2 (ja) 発芽バキュロウィルスを用いた蛋白質の発現と精製法
JP4545685B2 (ja) 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物
WO2001021792A1 (fr) Genes transporteurs oatp-b, c, d et e
WO2003083116A1 (fr) Procede de criblage d'inhibiteurs de transporteurs
WO2007037245A1 (fr) Polypeptide présentant une activité anti-angiogénique
US20050079539A1 (en) Novel gene encoding brain specific membrane protein
US7070978B2 (en) Method for expressing and purifying proteins using budded baculovirus
EP1981904B1 (fr) Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur hasct
CN107614527A (zh) 抗人膜类型adam28抗体
JPH03503721A (ja) 酵素的に活性な組換えグルコセレブロシダーゼ
WO2002022777A2 (fr) Genes cellulaires impliques dans l'oncogenese, les produits de ces genes et leurs applications diagnostiques et therapeutiques
US20050272029A1 (en) Hepatitis c viral-like particle purification

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase